• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多学科团队会议中的病例讨论对不可手术非小细胞肺癌患者的治疗和生存的影响。

The impact of case discussion at a multidisciplinary team meeting on the treatment and survival of patients with inoperable non-small cell lung cancer.

机构信息

Department of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.

出版信息

Intern Med J. 2009 Dec;39(12):838-41. doi: 10.1111/j.1445-5994.2009.02019.x.

DOI:10.1111/j.1445-5994.2009.02019.x
PMID:20233244
Abstract

Abstract Patients with inoperable non-small cell lung cancer diagnosed and managed at a single institution over a one-year period were identified. Those whose case had been discussed at a multidisciplinary meeting had better survival than those whose case was not discussed (mean survival; 280 days vs. 205 days, log-rank P= 0.048).

摘要

在一家机构被诊断和治疗的无法手术的非小细胞肺癌患者在一年内被识别出来。那些在多学科会议上讨论过病例的患者比那些没有讨论过病例的患者的生存时间更好(平均生存时间;280 天比 205 天,对数秩 P=0.048)。

相似文献

1
The impact of case discussion at a multidisciplinary team meeting on the treatment and survival of patients with inoperable non-small cell lung cancer.多学科团队会议中的病例讨论对不可手术非小细胞肺癌患者的治疗和生存的影响。
Intern Med J. 2009 Dec;39(12):838-41. doi: 10.1111/j.1445-5994.2009.02019.x.
2
Do multidisciplinary team meetings make a difference in the management of lung cancer?多学科团队会议对肺癌的管理有影响吗?
Cancer. 2011 Nov 15;117(22):5112-20. doi: 10.1002/cncr.26149. Epub 2011 Apr 26.
3
Management of stages I and II non-small-cell lung cancer in a New Zealand study: divergence from international practice and recommendations.新西兰一项关于I期和II期非小细胞肺癌管理的研究:与国际实践和建议的差异。
Intern Med J. 2008 Oct;38(10):758-68. doi: 10.1111/j.1445-5994.2007.01523.x. Epub 2008 Feb 20.
4
Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.不可切除的局部晚期非小细胞肺癌患者接受诱导化疗后序贯同步放化疗与单纯同步放化疗的疗效比较。
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):779-85. doi: 10.1016/j.ijrobp.2007.01.002. Epub 2007 Apr 6.
5
Intratumoral administration of cisplatin through a bronchoscope followed by irradiation for treatment of inoperable non-small cell obstructive lung cancer.通过支气管镜进行瘤内顺铂给药,随后进行放疗,用于治疗无法手术的非小细胞阻塞性肺癌。
Lung Cancer. 2006 Feb;51(2):225-36. doi: 10.1016/j.lungcan.2005.10.012. Epub 2005 Dec 15.
6
Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.接受手术切除的非小细胞肺癌且伴有单站N2疾病患者的长期生存情况。
J Thorac Cardiovasc Surg. 2004 Jul;128(1):130-7. doi: 10.1016/j.jtcvs.2003.11.061.
7
The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution.单机构16年间手术切除的IIIA期非小细胞肺癌治疗结果的演变
J Thorac Cardiovasc Surg. 2005 Dec;130(6):1601-10. doi: 10.1016/j.jtcvs.2005.08.010.
8
Analysis of multidisciplinary lung cancer practice.多学科肺癌诊疗实践分析
Intern Med J. 2007 Jan;37(1):18-25. doi: 10.1111/j.1445-5994.2006.01237.x.
9
Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer.III期(N2)非小细胞肺癌术前化疗与术前放化疗的比较
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1462-7. doi: 10.1016/j.ijrobp.2009.01.069. Epub 2009 May 19.
10
Trimodal therapy for histologically proven N2/3 non-small cell lung cancer: mid-term results and indicators for survival.组织学确诊的N2/3期非小细胞肺癌的三联疗法:中期结果及生存指标
Ann Thorac Surg. 2009 Jun;87(6):1676-83. doi: 10.1016/j.athoracsur.2009.03.068.

引用本文的文献

1
Early, integrated palliative care for people with chronic respiratory disease: lessons learnt from lung cancer.慢性呼吸道疾病患者的早期综合姑息治疗:从肺癌中汲取的经验教训
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666241305497. doi: 10.1177/17534666241305497.
2
Obstacles and drivers in the adoption of Standardized Structured Reporting (SSR): insights from pathologists.采用标准化结构化报告(SSR)的障碍与驱动因素:病理学家的见解
Virchows Arch. 2025 Jan 7. doi: 10.1007/s00428-024-04012-2.
3
Effectiveness of multi-disciplinary team management on 5-year overall survival for patients with stage III lung cancer.
多学科团队管理对Ⅲ期肺癌患者5年总生存率的有效性。
J Thorac Dis. 2024 Aug 31;16(8):5086-5096. doi: 10.21037/jtd-24-508. Epub 2024 Aug 28.
4
Multidisciplinary meeting review in nonsmall cell lung cancer: a systematic review and meta-analysis.多学科会议回顾在非小细胞肺癌中的应用:系统评价和荟萃分析。
Eur Respir Rev. 2024 May 8;33(172). doi: 10.1183/16000617.0157-2023. Print 2024 Apr 30.
5
The Best Supportive Care in Stage III Non-Small-Cell Lung Cancer.Ⅲ期非小细胞肺癌的最佳支持治疗。
Curr Oncol. 2023 Dec 29;31(1):183-202. doi: 10.3390/curroncol31010012.
6
Does Multidisciplinary Team Management Improve Clinical Outcomes in NSCLC? A Systematic Review With Meta-Analysis.多学科团队管理能否改善非小细胞肺癌的临床结局?一项Meta分析的系统评价
JTO Clin Res Rep. 2023 Sep 22;4(12):100580. doi: 10.1016/j.jtocrr.2023.100580. eCollection 2023 Dec.
7
The impact of a multidisciplinary team approach on the management of focal pancreatic lesions: a single tertiary center experience.多学科团队方法对胰腺局灶性病变管理的影响:单中心三级医院经验
Ann Gastroenterol. 2023 Sep-Oct;36(5):580-587. doi: 10.20524/aog.2023.0827. Epub 2023 Jul 25.
8
Adherence to interdisciplinary tumor board recommendations as an expression of quality-assured patient care: results of a bicentric German analysis.多学科肿瘤委员会建议的遵从性作为有质量保证的患者护理的表现:一项德中心分析的结果。
J Cancer Res Clin Oncol. 2023 Nov;149(16):14775-14784. doi: 10.1007/s00432-023-05253-5. Epub 2023 Aug 17.
9
Guideline adherence of tumor board recommendations in lung cancer and transfer into clinical practice.肺癌肿瘤委员会建议的遵循情况及向临床实践的转化。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11679-11688. doi: 10.1007/s00432-023-05025-1. Epub 2023 Jul 5.
10
Optimizing the structure of interdisciplinary tumor boards for effective cancer care.优化跨学科肿瘤多学科协作组的结构以实现有效的癌症护理。
Front Oncol. 2023 Apr 26;13:1072652. doi: 10.3389/fonc.2023.1072652. eCollection 2023.